연구동향 분석
박사

망막모세포종 치료에 있어서 Aflibercept 효과에 대한 전임상 연구 : Efficacy and safety of Aflibercept in preclinical animal models of retinoblastoma

김동윤 2015년

논문상세정보
인용/피인용
' 망막모세포종 치료에 있어서 Aflibercept 효과에 대한 전임상 연구 : Efficacy and safety of Aflibercept in preclinical animal models of retinoblastoma' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • aflibercept
  • angiogenesis
  • choroidal invasion
  • retinoblastoma
  • treatment
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
313 0

0.0%

' 망막모세포종 치료에 있어서 Aflibercept 효과에 대한 전임상 연구 : Efficacy and safety of Aflibercept in preclinical animal models of retinoblastoma' 의 참고문헌

  • Youssef NS, Said AM. Immunohistochemical expression of CD117 and vascular endothelial growth factor in retinoblastoma: possible targets of new therapies. International journal of clinical and experimental pathology 2014;7(9):5725-37.
  • Wild R, Ramakrishnan S, Sedgewick J, Griffioen AW. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image anal27ysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvascular research 2000;59(3):368-76.
  • Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. The New England journal of medicine 1991;324(1):1-8.
  • Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer chemotherapy and pharmacology 1989;24(3):148-54.
  • Tew WP, Colombo N, Ray-Coquard I, Del Campo JM, Oza A, Pereira D, et al. Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer 2014;120(3):335-43.
  • Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol 1990;108(1):128-32.
  • Shields CL, Shields JA. Diagnosis and management of retinoblastoma. Cancer control : journal of the Moffitt Cancer Center 2004;11(5):317-27.
  • Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT, et al. The Int24ernational Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006;113(12):2276-80.
  • Shields CL, Manjandavida FP, Lally SE, Pieretti G, Arepalli SA, Caywood EH, et al. Intra-arterial Chemotherapy for Retinoblastoma in 70 Eyes: Outcomes Based onthe International Classification of Retinoblastoma. Ophthalmology 2014;121(7):1453-60.
  • Scott IU, Murray TG, Feuer WJ, Van Quill K, Markoe AM, Ling S, et al. Externalbeam radiotherapy in retinoblastoma: tumor control and comparison of 2 techniques. Arch Ophthalmol 1999;117(6):766-70.
  • Schipper J, Tan KE, van Peperzeel HA. Treatment of retinoblastoma by precisionmegavoltage radiation therapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1985;3(2):117-32.
  • Sauerwein W, Hopping W, Bornfeld N. Radiotherapy for retinoblastoma. Treatment strategies. Frontiers of radiation therapy and oncology 1997;30:93-6.
  • Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 2007;104(47):18363-70.
  • Rossler J, Dietrich T, Pavlakovic H, Schweigerer L, Havers W, Schuler A, et al. Higher Vessel Densities in Retinoblastoma with Local Invasive Growth and Metastasis. The American journal of pathology 2004;164(2):391-4.
  • Rodriguez M. Ziv-aflibercept use in metastatic colorectal cancer. Journal of the advanced practitioner in oncology 2013;4(5):348-52.
  • Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for thetherapy of solid tumors and other disorders. Cancer research 1997;57(20):4593-9.
  • Phillips C, Sexton M, Wheeler G, McKenzie J. Retinoblastoma: review of 30 years' experience with external beam radiotherapy. Australasian radiology 2003;47(3):226-30.
  • Park SJ, Woo SJ, Park KH. Incidence of retinoblastoma and survival rate of retinoblastoma patients in Korea using the Korean National Cancer Registry database (1993-2010). Investigative ophthalmology & visual science 2014;55(5):2816-21.
  • Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligandsby VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15(2):171-85.28
  • Okimoto S, Nomura K. Clinical Manifestations and Treatment of Retinoblastoma in Kobe Children's Hospital for 16 Years. Journal of pediatric ophthalmology and strabismus 2014;51(4):222-9.
  • Naseripour M, Nazari H, Bakhtiari P, Modarres-zadeh M, Vosough P, Ausari M. Retinoblastoma in Iran: outcomes in terms of patients' survival and globe survival. BrJ Ophthalmol 2009;93(1):28-32.
  • Moroney JW, Sood AK, Coleman RL. Aflibercept in epithelial ovarian carcinoma.Future oncology 2009;5(5):591-600.
  • Marback EF, Arias VE, Paranhos A, Jr., Soares FA, Murphree AL, Erwenne CM. Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma. The British journal of ophthalmology 2003;87(10):1224-8.
  • Maciorowski Z, Klijanienko J, Padoy E, Mosseri V, Fourquet A, Chevillard S, et al.Comparative image and flow cytometric TUNEL analysis of fine needle samplesof breast carcinoma. Cytometry 2001;46(3):150-6.
  • Li FP, Abramson DH, Tarone RE, Kleinerman RA, Fraumeni JF, Jr., Boice JD, Jr.Hereditary retinoblastoma, lipoma, and second primary cancers. Journal of the National Cancer Institute 1997;89(1):83-4.
  • Lee SY, Kim DK, Cho JH, Koh JY, Yoon YH. Inhibitory effect of bevacizumab onthe angiogenesis and growth of retinoblastoma. Arch Ophthalmol 2008;126(7):953-8.
  • Lassoued W, Murphy D, Tsai J, Oueslati R, Thurston G, Lee WMF. Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. Cancer Biology& Therapy 2010;10(12):1326-33.
  • Kvanta A, Steen B, Seregard S. Expression of vascular endothelial growth factor(VEGF) in retinoblastoma but not in posterior uveal melanoma. Experimental eyeresearch 1996;63(5):511-8.
  • Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, et al. PotentVEGF blockade causes regression of coopted vessels in a model of neuroblastoma.Proc Natl Acad Sci U S A 2002;99(17):11399-404.
  • Kelly KJ, Sandoval RM, Dunn KW, Molitoris BA, Dagher PC. A novel method todetermine specificity and sensitivity of the TUNEL reaction in the quantitation ofapoptosis. American journal of physiology Cell physiology 2003;284(5):C1309-18.
  • Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials onanti-VEGF therapy for cancer. Nature clinical practice Oncology 2006;3(1):24-40.
  • Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins andVEGF. Oncogene 1999;18(38):5356-62.
  • Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al.Vessel cooption, regression, and growth in tumors mediated by angiopoietins andVEGF. Science 1999;284(5422):1994-8.
  • Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap:a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99(17):11393-8.
  • Harnett AN. Ocular radiotherapy: a review of current management. British journalof radiology Supplement 1988;22:122-32.
  • Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3):353-64.
  • Ghassemi F, Shields CL, Ghadimi H, Khodabandeh A, Roohipoor R. Combined Intravitreal Melphalan and Topotecan for Refractory or Recurrent Vitreous Seeding From Retinoblastoma. JAMA ophthalmology 2014.
  • Gaya A, Tse V. A preclinical and clinical review of aflibercept for the managementof cancer. Cancer treatment reviews 2012;38(5):484-93.26
  • Fortunato P, Pillozzi S, Tamburini A, Pollazzi L, Franchi A, La Torre A, et al. Irresponsiveness of two retinoblastoma cases to conservative therapy correlates with up- regulation of hERG1 channels and of the VEGF-A pathway. BMC cancer 2010;10:504.
  • Folkman J. Tumor angiogenesis: therapeutic implications. The New Englandjournal of medicine. 1971;285(21):1182-6.
  • Folkman J. Endothelial cells and angiogenic growth factors in cancer growth andmetastasis. Introduction. Cancer metastasis reviews 1990;9(3):171-4.
  • Folkman J, Cotran R. Relation of vascular proliferation to tumor growth. International review of experimental pathology 1976;16:207-48.
  • Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and biophysical research communications 2005;333(2):328-35.
  • Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature reviews Drug discove25ry 2004;3(5):391-400.
  • Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nudemouse. Journal of surgical oncology 1986;31(4):229-34.
  • Eichten A, Adler AP, Cooper B, Griffith J, Wei Y, Yancopoulos GD, et al. Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models. Angiogenesis 2013;16(2):429-41.
  • Cowell JK, Ramani P, Song Y, Evans M, Morgan G. The use of SCID mice for thegrowth of retinoblastoma cell lines and for the establishment of xenografts from primary tumours. European journal of cancer 1997;33(7):1070-4.
  • Chiron M, Bagley RG, Pollard J, Mankoo PK, Henry C, Vincent L, et al. Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograftmodels of colorectal cancer. Molecular cancer therapeutics 2014;13(6):1636-44.
  • Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 2009;93(1):21-3.
  • Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growthfactor withdrawal. The Journal of clinical investigation 1999;103(2):159-65.
  • Balmer A, Zografos L, Munier F. Diagnosis and current management of retinoblastoma. Oncogene 2006;25(38):5341-9.
  • Arean C, Orellana ME, Abourbih D, Abreu C, Pifano I, Burnier MN, Jr. Expression of vascular endothelial growth factor in retinoblastoma. Arch Ophthalmol 2010;128(2):223-9.
  • Anteby I, Ramu N, Gradstein L, Miskin H, Pe'er J, Benezra D. Ocular and orbital complications following the treatment of retinoblastoma. Eur J Ophthalmol 1998;8(2):106-11.
  • Allen JW, Moon J, Redman M, Gadgeel SM, Kelly K, Mack PC, et al. SouthwestOncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan Withand Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014.
  • Albini A, Melchiori A, Garofalo A, Noonan DM, Basolo F, Taraboletti G, et al. Matrigel promotes retinoblastoma cell growth in vitro and in vivo. International journal of cancer Journal international du cancer 1992;52(2):234-40.
  • Abramson DH, Ellsworth RM, Grumbach N, Sturgis-Buckhout L, Haik BG. Retinoblastoma: correlation between age at diagnosis and survival. Journal of pediatric ophthalmology and strabismus 1986;23(4):174-7.
  • Abramson DH, Ellsworth RM, Grumbach N, Kitchin FD. Retinoblastoma: survival,age at detection and comparison 1914-1958, 1958-1983. Journal of pediatric ophthalmology and strabismus 1985;22(6):246-50.